<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00116324</url>
  </required_header>
  <id_info>
    <org_study_id>2002-P-001696</org_study_id>
    <nct_id>NCT00116324</nct_id>
  </id_info>
  <brief_title>Predicting the Response to Montelukast by Genetic Variation in Asthmatics</brief_title>
  <official_title>Predicting the Bronchoprotective Response to a Leukotriene Modifier by Genetic Polymorphism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine a specific variation in the genetic code for an&#xD;
      enzyme (LTC4 synthase) which plays an important role in the airway inflammation associated&#xD;
      with asthma. We hypothesize that asthmatic patients with this variant gene will have a better&#xD;
      response to montelukast than patients with the wild type gene, as measured by the ability of&#xD;
      montelukast to protect against a hypertonic saline challenge.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple genetic polymorphisms in the leukotriene pathway have been described but their&#xD;
      clinical relevance is unclear. A single nucleotide polymorphism in the LTC4 synthase promoter&#xD;
      region has been associated with increased LTC4 synthase mRNA and a trend toward improved&#xD;
      bronchodilatory response to leukotriene modifiers in severe asthmatics. This study will&#xD;
      examine mild to moderate asthmatics with the variant gene and evaluate the bronchoprotective&#xD;
      response of montelukast in a double-blind, placebo-controlled cross-over fashion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">December 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hypertonic saline PD20</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved asthma control</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exhaled breath condensate inflammatory markers</measure>
  </secondary_outcome>
  <enrollment>150</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female subjects, age 18-55&#xD;
&#xD;
          -  Clinical history consistent with asthma&#xD;
&#xD;
          -  Mild to moderate asthma as determined by pulmonary function tests--60% or higher of&#xD;
             predicted FEV1 for age, sex and race.&#xD;
&#xD;
          -  Response to hypertonic saline, which will be the main outcome variable measured.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Smokers (total lifetime smoking history&gt;10 pack-years, any in the past year)&#xD;
&#xD;
          -  Pregnant woman-if of childbearing age, not using an acceptable form of birth control.&#xD;
&#xD;
          -  Use of a leukotriene modifier within the past month&#xD;
&#xD;
          -  Use of inhaled or oral steroids within the past month.&#xD;
&#xD;
          -  Emergency room visit for asthma exacerbation within the past 6 weeks.&#xD;
&#xD;
          -  Intubation for asthma exacerbation in the past 10 years.&#xD;
&#xD;
          -  Adverse reaction to inhaled beta-agonists in the past.&#xD;
&#xD;
          -  No recent (past 48 hours) use of anticholinergics, theophylline, antihistamines,&#xD;
             pseudoephedrine.&#xD;
&#xD;
          -  Patients will also be asked not to use any short acting beta-agonists for 6 hours and&#xD;
             long-acting beta-agonists for 48 hours before their initial visit (when pulmonary&#xD;
             function evaluation will be performed).&#xD;
&#xD;
          -  Lung disease other than asthma&#xD;
&#xD;
          -  Significant medical illness other than asthma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elliot Israel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Drazen JM, O'Brien J, Sparrow D, Weiss ST, Martins MA, Israel E, Fanta CH. Recovery of leukotriene E4 from the urine of patients with airway obstruction. Am Rev Respir Dis. 1992 Jul;146(1):104-8.</citation>
    <PMID>1320817</PMID>
  </reference>
  <reference>
    <citation>Taylor GW, Taylor I, Black P, Maltby NH, Turner N, Fuller RW, Dollery CT. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet. 1989 Mar 18;1(8638):584-8.</citation>
    <PMID>2564113</PMID>
  </reference>
  <reference>
    <citation>Drazen JM, Yandava CN, Dub√© L, Szczerback N, Hippensteel R, Pillari A, Israel E, Schork N, Silverman ES, Katz DA, Drajesk J. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet. 1999 Jun;22(2):168-70.</citation>
    <PMID>10369259</PMID>
  </reference>
  <reference>
    <citation>In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, Silverman ES, Collins T, Fischer AR, Keith TP, Serino K, Kim SW, De Sanctis GT, Yandava C, Pillari A, Rubin P, Kemp J, Israel E, Busse W, Ledford D, Murray JJ, Segal A, Tinkleman D, Drazen JM. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest. 1997 Mar 1;99(5):1130-7.</citation>
    <PMID>9062372</PMID>
  </reference>
  <reference>
    <citation>Sanak M, Simon HU, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet. 1997 Nov 29;350(9091):1599-600.</citation>
    <PMID>9393345</PMID>
  </reference>
  <reference>
    <citation>Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST, Holloway JW, Sayers I. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax. 2000 Oct;55 Suppl 2:S28-31.</citation>
    <PMID>10992553</PMID>
  </reference>
  <reference>
    <citation>Anderson PJ, Garshick E, Blanchard JD, Feldman HA, Brain JD. Intersubject variability in particle deposition does not explain variability in responsiveness to methacholine. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):649-54.</citation>
    <PMID>1892306</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>June 28, 2005</study_first_submitted>
  <study_first_submitted_qc>June 28, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2005</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Elliot Israel, MD</investigator_full_name>
    <investigator_title>Physician</investigator_title>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Leukotriene receptor antagonist</keyword>
  <keyword>Hypertonic saline challenge</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

